CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

206088Orig1s000

ENVIRONMENTAL ASSESSMENT

Version: 11/24/2011

DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION				EAS REVIEW REQUEST		
TO: ENVIRONMENTAL ASSESSMENT STAFF				FROM (Name, Title, Office/Division): Kerri-Ann Jennings, PM, ONDQA/X62919 c/o Requestor- CMC Lead, Shulin Ding		
E-mail to: CDER OPS IO EA Paper mail to: WO Bldg 51, Room 4193				Primary CMC Reviewer- Caroline Strasinger		
REQUEST DATE	IND#		/ ANDA	TYPE OF	DATE OF DOCUMENT	
05 NOV 2013		I `	A 206088	DOCUMENT Electronic	23 SEPT 2013	
NAME OF DRUG apremilast		PRIORITY CONSIDERATION NME		PDUFA DATE	DESIRED COMPLETION DATE	
				23 SEPT 2014	28 FEB 2014	
NAME OF APPLICANT OR SPONSOR: Celgene						
GENERAL PROVISIONS IN APPLICATION						
 ☑ ENVIRONMENTAL ASSESSMENT ☑ ENVIRONMENTAL IMPACT STATEMENT ☑ CLAIM OF CATEGORICAL EXCLUSION ☑ OTHER 						
E CLAIM OF CATEGORICAL EXCLUSION UTILER						
EDR Link: \\\CDSESUB1\EVSPROD\\NDA206088\\206088.enx						
eCTD Sequence Number: 0000						
COMMENTS / SPECIAL INSTRUCTIONS:						
Please evaluate the applicant's claim for categorical exclusion from preparation of an Environmental Assessment for NDA 206088.						
Please note that NDA 206088 is submitted to Division of Dermatology and Dental Products for the indication of psoriasis. The same product is also the subject of NDA 205437 submitted to Division of Pulmonary, Allergy, and Rheumatology Products. NDA 205437 was received by CDER on March 21, 2013. Its PDUFA date is March 21, 2014.						
SIGNATURE OF REQUESTER: DOCUMENTS				S FOR REVIEW DE	LIVERED BY (Check one):	
			□ EDR □	E-MAIL MAII	L HAND	

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.
/s/
KERRI-ANN JENNINGS 11/07/2013